Report: More than half of the world's population will be overweight/obese by 2035

Published Date: 08 Mar 2023

The World Health Organization's 2023 Atlas predicts that 51% of the world's population, or more than 4 billion people, will be overweight or obese within the next 12 years.

Read Full News

Latest News

Endocrine Society Launches New Initiatives Around Obesity

A new scientific statement was published and Center on Obesity was launched simultaneously.

New Guidance Addresses Diabetes and Smoking Cessation

The issue is underemphasized in clinical diabetes care, authors say.

Retatrutide: It’s Already in Your Waiting Room

Social media has triggered a retatrutide tsunami. What can clinicians do when patients disclose taking an unapproved weight-loss drug?

Whole-Plant Extract Outperforms THC on Glycemia

Whole-plant cannabis extract beats THC alone at improving glucose control in obese mice. Here's what the science means for patient conversations.

Novo Nordisk Says Wegovy Approved in China for MASH

Denmark's Novo Nordisk ⁠said on Thursday its blockbuster ⁠weight-loss drug Wegovy had ⁠been approved ‌in China as the first GLP-1 RA class of drugs for the ‌treatment of MASH.

Weekly Basal Insulin + Semaglutide Combo May Benefit T2D

Novo Nordisk’s phase 3b trial shows once-weekly IcoSema improves glycemic control and weight with less hypoglycemia than insulin glargine U100 in adults with type 2 diabetes.

Todays Updates

First-Line T-DXd Boosts PFS in HER2-Mutant NSCLC

DESTINY-Lung04 supports trastuzumab deruxtecan as a new frontline option for patients with advanced HER2-mutant disease, though it failed to improve overall survival.

Could Burnout Become the Employer’s Responsibility?

A European Parliament committee is backing employer risk assessments to tackle burnout. But should that mean new binding EU rules?

High CLL Remission Seen With First-Line Triplet Regimen

High 2-year survival rates are seen in treatment-naive patients with CLL receiving a noncovalent BTK inhibitor combined with venetoclax and obinutuzumab.

FET-PET Agent Approved for Glioma Imaging

Floretyrosine F18 is the first amino acid PET imaging agent approved for glioma in the United States.

Todays Updates

First-Line T-DXd Boosts PFS in HER2-Mutant NSCLC

DESTINY-Lung04 supports trastuzumab deruxtecan as a new frontline option for patients with advanced HER2-mutant disease, though it failed to improve overall survival.

Could Burnout Become the Employer’s Responsibility?

A European Parliament committee is backing employer risk assessments to tackle burnout. But should that mean new binding EU rules?

High CLL Remission Seen With First-Line Triplet Regimen

High 2-year survival rates are seen in treatment-naive patients with CLL receiving a noncovalent BTK inhibitor combined with venetoclax and obinutuzumab.

FET-PET Agent Approved for Glioma Imaging

Floretyrosine F18 is the first amino acid PET imaging agent approved for glioma in the United States.

Latest News

A new scientific statement was published and Center on Obesity was launched simultaneously.

The issue is underemphasized in clinical diabetes care, authors say.

Social media has triggered a retatrutide tsunami. What can clinicians do when patients disclose taking an unapproved weight-loss drug?

Whole-plant cannabis extract beats THC alone at improving glucose control in obese mice. Here's what the science means for patient conversations.

Denmark's Novo Nordisk ⁠said on Thursday its blockbuster ⁠weight-loss drug Wegovy had ⁠been approved ‌in China as the first GLP-1 RA class of drugs for the ‌treatment of MASH.

Novo Nordisk’s phase 3b trial shows once-weekly IcoSema improves glycemic control and weight with less hypoglycemia than insulin glargine U100 in adults with type 2 diabetes.

News All Time

Novo Scraps Two More Heart Drug Trials, Further Dimming Growth Beyond Obesity

Novo Nordisk said on Monday it had halted two ⁠additional trials of its experimental cardiovascular drug ziltivekimab, further denting the Danish drugmaker's ⁠efforts to...

MicroRNA Panel May Predict Early Liver Metastasis in PDAC

A machine learning model using 7 exosomal microRNAs can identify patients with pancreatic ductal adenocarcinoma at risk for early liver metastasis.

Can a Smoothie Boost GLP-1 Naturally?

Certain foods and products can support individuals taking GLP-1s for weight management, but they can’t boost GLP-1 production or be used rather than medications.

Metyrapone Linked to Improved Quality of Life in Cushing

Metyrapone is associated with progressive improvements in quality of life among patients with Cushing syndrome, with recovery timing and patterns varying across symptom domains.

How to Help Manage Depression After GLP-1 Weight Regain

Offer realistic expectations when medication use ends and provide the tools to remain on track.

Indian Activists Lodge Concerns About Food Warning Proposal

Activists spearheading calls for food labelling said a government proposal to have red warnings only when two concerning nutrients are high created ⁠an "industry-friendly loophole".

EMA Probes Injectable Iron Medicines for Bone Risks

European regulators launched a safety review of injectable iron medicines following reports of severe hypophosphatemia and osteomalacia.

US FDA Is Working With Manufacturers to Boost Estrogen Patch Supply Amid Access Concerns

The U.S. health regulator said on Thursday it is working with all six manufacturers to increase the supply of estradiol transdermal patches, ⁠used to treat menopause...

Medicare A1c Coverage Boosts Prediabetes Detection

Since Medicare began covering A1c for diabetes screening in 2024, use of the test and detection of prediabetes have risen dramatically among older adults.

GLP-1 Meds Linked to Symptomatic Remission in UC

GLP-1 receptor agonist therapy is linked to higher symptomatic remission rates among patients with ulcerative colitis, with benefits appearing independent of weight loss.

Keto Diet Outperforms Others in Liver Health in Obesity

Liver health improves more on a very-low-carbohydrate ketogenic diet than on a Mediterranean or very-low-fat plant-forward diet.

From Hunger to Obesity: Developing World Faces Growing Threat to Child Health

Intan Permatasari's mother simply couldn't refuse her daughter's pleas for food. By the time she was 4, Intan had outgrown all the kindergarten uniforms and had to wear...

US Pentagon Issues Clinical Guidelines on Troop Testosterone Screening to Start Immediately

The U.S. Pentagon issued detailed guidance on Wednesday for a new, mandatory testosterone deficiency screening policy ⁠for active-duty and reserve service members age 30 and...

Earlier SGLT2 Use After AKI May Improve Outcomes

Earlier SGLT2 inhibitor use after dialysis-requiring AKI is linked to better kidney outcomes in patients with type 2 diabetes, with no increase in safety events.

New Tool Helps Clinicians Screen for Obesity’s Causes

Experts have developed a new 25-minute tool to screen patients for over 30 possible causes of obesity, from genetics to psychological trauma.

Too Weak, Too Strict: India's Food Warning Labels Draw Fire From All Sides

The Indian government is facing fierce opposition on proposed food warning labels from both health experts and food giants - activists say many items will escape scrutiny...

Recommended News For You

In advanced endometrial cancer, immunocheckpoint inhibitor-chemotherapy combination improves overall survival.

Clinical trial is testing whether heavy lifting could combat cancer side effects

Omitting Biopsy After Negative MRI Halves Diagnoses of Insignificant Prostate Cancer

EU Flags Shortage Of Schizophrenia Drug Injections Due to Manufacturing Issues

Drugmaker Pulls Trodelvy's Bladder Cancer Approval

EMA Recommends Generic in Advanced/Metastatic Breast Cancer

A healthier lifestyle after bowel screening shown to prevent bowel cancer

Recommended Articles For You

Reshaping the Battlefield Through Tumor Microenvironment Modulation for Cancer Therapy 

Hematopoietic Microenvironment Rejuvenation Through Cellular Architecture Remodeling 

Neuroendocrine Tumors: Mechanisms of Mortality, Associated Conditions 

Engineered Hematopoietic Cells for Targeted Correction of Abnormal Blood-Cell Production 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Sevabertinib Approved for First-Line Mutated NSCLC

2.

Top 10 questions about breast cancer answered

3.

Inadvertent lung cancer screening results are discussed in a new study.

4.

United States Lung Cancer Screening Rates Remain Low. s. in particular in the South.

5.

Study indicates that exercise can help colon cancer survivors live as long as matched individuals

1.

Red Blood Cell Microparticles: Tiny Warriors Against Bleeding in the Brain

2.

An Analytical and Statistical Journey through Genomic Revolution, Novel Therapeutics, and Future Horizons in Lymphoma 2025

3.

Neoadjuvant Radiotherapy & Endocrine Therapy in ER+ Breast Cancer Treatment

4.

A New Hope: Exploring the Potential of Pegaspargase in Treating Cancer

5.

CA-125 Test: Why It's Important for Women's Health and Early Detection of Ovarian Cancer

1.

International Cancer Conference

2.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

3.

International Cancer Conference

4.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part V

2.

Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias

3.

What Therapy Would Yield the Best Outcomes In Patients with R/R B-cell ALL?

4.

Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part II

5.

Breaking Down PALOMA-2: How CDK4/6 Inhibitors Redefined Treatment for HR+/HER2- Metastatic Breast Cancer

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot